文献速递美容整形颅颌面外科显微修复重建

静脉氨甲环酸不增加头颈整形重建术后静脉血栓栓塞风险

Does Intravenous Tranexamic Acid Impact Risk of Venous Thromboembolism in Plastic & Reconstructive Surgery of the Head and Neck?
PubMed 文献 · Plast Reconstr Surg · 2026-02-03

本研究基于Fortuna行政索赔数据库(超2亿患者)开展回顾性队列研究,纳入2010–2024年接受头颈整形与重建手术的成人患者,比较术中静脉使用氨甲环酸(TXA)与未使用者的90天静脉血栓栓塞(VTE)风险。经倾向评分匹配及逆概率加权调整后,TXA组VTE发生率为0.2%,非TXA组为0.28%,加权逻辑回归显示无统计学显著差异(OR 0.62,95%CI 0.13–3.04,p=0.55)。结论认为静脉TXA不增加术后VTE风险,支持其作为安全止血辅助用药继续使用。

要点

  • 头颈整形重建术中静脉TXA组90天VTE发生率为0.2%,非TXA组为0.28%。
  • 加权逻辑回归显示VTE风险无显著差异(OR 0.62,95%CI 0.13–3.04,p=0.55)。
  • 结果支持静脉TXA可作为头颈整形重建手术的安全止血辅助用药。

核心结论

  • 头颈整形与重建手术中静脉使用TXA与术后90天VTE风险升高无关,支持其作为安全止血辅助用药继续使用。

研究设计与样本

  • 回顾性队列研究,使用Fortuna行政索赔数据库(超2亿患者),纳入2010–2024年接受头颈整形与重建手术的成人患者。
  • 通过CPT编码识别手术,确定手术当日是否接受静脉TXA,主要结局为术后90天内VTE诊断。
  • 采用高维倾向评分匹配联合逆概率治疗加权(IPTW)调整基线人口学、合并症、药物暴露及医疗利用情况,并以逻辑回归评估关联。

主要发现

  • 共1,011例患者接受静脉TXA,157,959例未接受。
  • 倾向评分匹配后两组基线均衡,TXA组VTE发生率为0.2%,非TXA组为0.28%。
  • 加权逻辑回归显示VTE风险无统计学显著差异(OR 0.62,95%CI 0.13–3.04,p=0.55)。

临床怎么用

  • 在头颈整形与重建手术中,可考虑静脉使用TXA以减少围手术期出血,而不必担心增加90天VTE风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) is widely used in surgery to reduce perioperative bleeding, but concerns persist regarding its potential thromboembolic risks. This study evaluates the association between intraoperative intravenous (IV) TXA use and 90-day postoperative venous thromboembolism (VTE) risk in patients undergoing plastic and reconstructive surgery of the head and neck. METHODS: We conducted a retrospective cohort study using the Fortuna database, a national administrative claims dataset with over 200 million patients. Adult patients undergoing plastic and reconstructive surgery between 2010 and 2024 were identified using CPT codes, and whether they received IV TXA on the index day of procedure was determined. The primary outcome was VTE diagnosis within 90 days postoperatively. Use of enoxaparin or heparin was also documented. High-dimensional propensity score matching with inverse probability of treatment weighting (IPTW) was used to adjust for baseline demographics, comorbidities, medication exposures, and healthcare utilization. Logistic regression was used to evaluate the association between treatment and the binary outcome. RESULTS: A total of 1,011 patients received IV TXA and 157,959 did not. After propensity score matching, the two groups were well-balanced. The incidence of VTE was 0.2% in the TXA group, and 0.28% in the non-TXA group. Weighted logistic regression demonstrated no statistically significant difference in VTE risk (OR 0.62, 95% CI: 0.13-3.04, p = 0.55). CONCLUSIONS: IV TXA use was not associated with increased postoperative VTE risk in plastic and reconstructive surgery of the head and neck, supporting its continued use as a safe hemostatic adjunct in this patient population.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Wei EX, Fu B, Muralidharan J, et al. Does Intravenous Tranexamic Acid Impact Risk of Venous Thromboembolism in Plastic & Reconstructive Surgery of the Head and Neck? Plast Reconstr Surg. 2026. PMID: 41637204. doi:10.1097/PRS.0000000000012887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。